294 results
8-K
EX-99.1
INSM
Insmed Incorporated
8 Aug 24
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
7:00am
of 2024, compared to $16.6 million for the second quarter of 2023, primarily reflecting increased sales volumes of ARIKAYCE.
Research and development (R&D …
Operating expenses:
Cost of product revenues (excluding amortization of intangible assets)
Research and development
Selling, general and administrative
8-K
EX-99.2
INSM
Insmed Incorporated
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
of common stock.
Insmed intends to use the net proceeds from this offering to fund continued research and development of brensocatib as well as pre … of ARIKAYCE® (amikacin liposome inhalation suspension), further research and development of treprostinil palmitil inhalation powder (TPIP) and any
424B5
INSM
Insmed Incorporated
30 May 24
Prospectus supplement for primary offering
4:02pm
research and development of brensocatib as well as pre-commercial and, if approved, commercialization activities related to brensocatib, activities … related to the further commercialization and development of ARIKAYCE, further research and development of TPIP and any of our other research product
424B5
INSM
Insmed Incorporated
28 May 24
Prospectus supplement for primary offering
7:14pm
business, including any pricing reform and laws that impact our ability to utilize certain third parties in the research, development or manufacture … of proceeds
We intend to use the net proceeds we receive from this offering to fund continued research and development of brensocatib as well as pre
8-K
EX-99.1
qpg760l
9 May 24
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
7:05am
8-K
0jdgru
22 Feb 24
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
7:58am
8-K
EX-99.1
jknopenfdhh1
22 Feb 24
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
7:58am
424B5
nnu 20ktj066oz
22 Feb 24
Prospectus supplement for primary offering
7:43am
8-K
EX-99.1
gv6pcpadm
26 Oct 23
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
7:38am
8-K
EX-99.1
1zujrq
3 Aug 23
Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
7:30am
S-3ASR
eu99lyreamh
19 May 23
Automatic shelf registration
4:20pm
8-K
EX-99.2
td2drk33 sp4
8 May 23
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, “The
7:45am
8-K
EX-99.1
323tbuov48misnfj2
4 May 23
Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
7:30am